RenovoRx Unveils Groundbreaking Pre-Clinical Data at SSO 2025 A New Frontier in Targeted Cancer Therapy, | CSIMarket News
CSI Market
Sign In | Register

RenovoRx Unveils Groundbreaking Pre-Clinical Data at SSO 2025 A New Frontier in Targeted Cancer Therapy,

Published | Modified
CSIMarket Newsroom | CSIMarket.com
Illustrative image

In an important development for cancer treatment, RenovoRx, Inc. (Nasdaq: RNXT) a pioneering life sciences firm announced the upcoming presentation of groundbreaking pre-clinical data at the Society of Surgical Oncology (SSO) 2025 Annual Meeting. The event, scheduled for March 18-21, 2025, will serve as a platform for medical professionals, researchers, and industry stakeholders to gather and discuss the latest advancements in surgical oncology.

The highlighted research abstract, en
Sources for this article: Based on Renovorx Inc ’s official statement and CSIMarket.com Customer Analytics Research for Renovorx Inc
For details on how CSIMarket validates financial and corporate news, please review our Editorial Standards & Fact-Checking Policy .
Tags:
#BusinessUpdate, #NasdaqCompany, #customers, #Nasdaq, #, #, #, #RNXT, #Renovorx Inc, #Major Pharmaceutical Preparations
Share this article:
X LinkedIn Facebook Email
Link copied to clipboard.

Comments

Comments are available to active subscribers. Subscribe or Log in.
Get the full CSIMarket dataset: Subscribe API License